GLP-1 (Glucagon-Like Peptide-1) is an incretin hormone naturally secreted by the gut in response to food intake.
It stimulates insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite.
Synthetic GLP-1 receptor agonists (such as liraglutide and exenatide) are FDA-approved for type 2 diabetes and obesity.
Beyond these approved uses, GLP-1 and its analogs are being studied in research settings for broader roles in metabolism, cardiovascular health, and neuroprotection.
How It Is Used in Research Settings
- Investigated for weight loss and appetite suppression through central nervous system pathways.
- Studied for improving insulin sensitivity and glucose control in type 2 diabetes and metabolic syndrome models.
- Explored in cardiovascular research for reducing inflammation and atherosclerosis risk.
- Examined for potential neuroprotective effects in models of Alzheimer’s disease and Parkinson’s disease.
Proposed Uses (Research Areas)
- Metabolic health — type 2 diabetes, obesity, and insulin resistance.
- Cardiovascular research — improving lipid profiles and reducing risk markers.
- Neuroprotection — potential applications in neurodegenerative diseases.
- Liver health — studied in non-alcoholic fatty liver disease (NAFLD) and NASH models.
How It Is Dosed in Research Settings
- Injectable: Subcutaneous injections ranging from 0.25 mg to 2.4 mg weekly are studied, or 0.6 mg to 1.8 mg daily in older protocols (liraglutide analog).
- Cycle length: Research studies often run for 12–52 weeks depending on endpoints such as weight loss, HbA1c reduction, or cardiovascular risk improvement.
- Handling: Reconstituted from lyophilized form (where applicable) or supplied as solution pens; stored refrigerated per research SOPs.
Important Considerations
- Regulatory status: Several GLP-1 receptor agonists are FDA-approved for type 2 diabetes and obesity, but other uses remain experimental.
- Evidence base: Supported by large-scale clinical trials for approved indications; neuroprotective, cardiovascular, and liver health uses remain under investigation.
- Safety: Reported side effects include nausea, vomiting, delayed gastric emptying, and rare risks such as pancreatitis. Long-term safety for non-approved indications is unestablished.
Disclaimer
This material is provided for educational purposes only and summarizes published research on GLP-1.
It is not medical advice. Except for its FDA-approved indications, GLP-1 use is considered experimental and should not be viewed as a general therapy for medical use.
This peptide is for research use only.